Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with ...
The standard test for differentiating between pituitary and ectopic adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome is corticotropin-releasing hormone (CRH)-stimulated inferior ...
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December ...
Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced that the first patient has been ...
Drexel practices a No Harm Test-Optional review for fall entry. This means, with some exceptions, applicants can choose whether to include standardized test scores as part of their application to the ...
Recordati Rare Diseases Canada Inc. announced today the Canadian product availability of ISTURISA® (osilodrostat) for the ...
Mark Gurarie is a writer covering health topics, technology, music, books, and culture. He also teaches health science and research writing at George Washington University's School of Medical and ...
Carley Millhone is a writer and editor based in the Midwest who covers health, women's wellness, and travel. Her work has appeared in publications like SELF, Greatist, and PureWow. Jay N. Yepuri, MD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback